Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01476787 · ClinicalTrials.gov registry record · Phase 3

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

A Phase 3 study of Follicular Lymphoma, sponsored by Celgene.

Completed
Registry status
Phase 3
Development phase
1,030
Enrollment target
20
Study locations

NCT01476787 is a Phase 3 study of Follicular Lymphoma that has completed, run by Celgene. The registered enrollment target is 1,030 participants, above the 124-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (731% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01476787, a Phase 3 study of Follicular Lymphoma, has completed, sponsored by Celgene.

COMPLETED
Registry status
Phase 3
Development phase
1,030 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.

Conditions Studied

Follicular Lymphoma

Interventions

  • DRUG Rituximab
  • DRUG Lenalidomide
  • DRUG Rituximab-CHOP
  • DRUG Rituximab-CVP
  • DRUG Rituximab-Bendamustine

Study Locations (20)

New Jersey

  • Local Institution - 54403 - Cherry Hill
  • Local Institution - 53703 - Hackensack
  • Local Institution - 50903 - Morristown
  • Local Institution - 54303 - Sparta

Florida

  • Local Institution - 52503 - Englewood
  • Local Institution - 51703 - Orlando
  • Local Institution - 53803 - St. Petersburg

California

  • Local Institution - 51803 - Fullerton
  • Local Institution - 52003 - Los Angeles

Massachusetts

  • Local Institution - 50403 - Boston
  • Local Institution - 50503 - Boston

New York

  • Local Institution - 52403 - New York
  • Local Institution - 50203 - New York

Arizona

  • Local Institution - 54103 - Chandler

Colorado

  • Local Institution - 51603 - Colorado Springs

Illinois

  • Local Institution - 50803 - Chicago

Trial Details

FieldValue
Enrollment Target 1,030 participants
Start Date 2011-12-29
Est. Completion 2024-04-30
Phase Phase 3

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01476787

The ClinicalTrials.gov registry entry for NCT01476787 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,030 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 124-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (731% higher). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Rituximab is the first listed.

NCT01476787 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New Jersey, Florida, California.

Frequently Asked Questions

What is clinical trial NCT01476787 about?

NCT01476787 is a clinical study titled "Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma". The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.

What is the current status of trial NCT01476787?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,030 participants. The study started on 2011-12-29. Estimated completion is 2024-04-30.

What conditions does trial NCT01476787 study?

This clinical trial studies the following conditions: Follicular Lymphoma.

What interventions are being tested in trial NCT01476787?

The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG), Rituximab-CHOP (DRUG), Rituximab-CVP (DRUG), Rituximab-Bendamustine (DRUG).

Who is sponsoring clinical trial NCT01476787?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01476787 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Follicular Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Follicular Lymphoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.